Margaret Paggiosi
Sheffield Teaching Hospitals NHS Foundation Trust · University of Sheffield
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Margaret Paggiosi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:56 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT01293292 · Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of ActionSheffield Teaching Hospitals NHS Foundation Trust · completed · Osteoporosis · principal investigator
- Ph2NCT00666627 · Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential EffectsSheffield Teaching Hospitals NHS Foundation Trust · completed · Post-menopausal Osteoporosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:56 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.Osteoporos Int · 2016123 citationsRCR 5.8
- Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.Osteoporos Int · 201447 citationsRCR 2.0
- The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.Bone · 201028 citationsRCR 0.9
- Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.Osteoporos Int · 201824 citationsRCR 1.4
- Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.J Clin Endocrinol Metab · 201818 citationsRCR 0.8
- High-impact exercise stimulated localised adaptation of microarchitecture across distal tibia in postmenopausal women.Osteoporos Int · 202118 citationsRCR 1.8
- 16 citationsRCR 1.1
- Adherence to raloxifene therapy: assessment methods and relationship with efficacy.Osteoporos Int · 20139 citationsRCR 0.4
- Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study.J Bone Miner Res · 20246 citationsRCR 0.8
- Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy.J Clin Densitom · 20104 citationsRCR 0.1